Q2 FY2026 EarningsQ2 FY2026 beat consensus on the top line with revenue of $176.2M vs. $166.4M expected, driven by 46% YoY growth in LIVMARLI sales. However, EPS of -$1.06 significantly missed the -$0.74 consensus due to higher-than-anticipated operating expenses, including a $16.4M non-recurring IPR&D charge. Positive commercial momentum led management to raise FY2026 product sales guidance to $680M-$700M, though the volixibat NDA for PSC is now delayed to H1 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Mirum Pharmaceuticals(MIRM) the Revenue is 176.24 M (+37.92%), Beat estimate;the EBIT is -42.54 M (-752.6%), Miss estimate;the EPS is -1.06 (-783.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.18B37.92%
0.17B30.20%
+0.01B7.72%
EBITMiss expectations
-0.04B752.62%
-0.04B645.61%
-0.01B107.01%
EPSMiss expectations
-1.06783.33%
-0.7431519.28%
-0.3169264.05%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf